15 September 2022  
EMA/CHMP/757723/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Xalkori 
crizotinib 
On 15 September 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Xalkori. The marketing authorisation holder for this medicinal product is Pfizer Europe MA EEIG. 
The CHMP adopted 2 new indications for the treatment of paediatric patients with anaplastic large cell 
lymphoma (ALCL) or inflammatory myofibroblastic tumour (IMT). For information, the full indications for 
Xalkori will therefore be as follows:2 
Xalkori as monotherapy is indicated for: 
• 
• 
• 
• 
• 
The first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive 
advanced non-small cell lung cancer (NSCLC) 
The treatment of adults with previously treated anaplastic lymphoma kinase 
(ALK)-positive advanced non-small cell lung cancer (NSCLC) 
The treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC) 
The treatment of paediatric patients (age ≥6 to <18 years) with relapsed or 
refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large 
cell lymphoma (ALCL) 
The treatment of paediatric patients (age ≥6 to <18 years) with recurrent or 
refractory anaplastic lymphoma kinase (ALK)-positive unresectable 
inflammatory myofibroblastic tumour (IMT) 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
